Inventiva S.A. (IVEVF)
OTC Markets OTCPK
Price as at 1 Oct 2026, 01:16 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Inventiva S.A. trades at $3.22. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Inventiva S.A.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its IVEVF data?
Fundamentals for IVEVF come from company filings and exchange data, as listed on OTC Markets OTCPK; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 01:16 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for IVEVF, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.